Global Oncology Academy

Recognizing the Role of Capmatinib for METex14 in NSCLC

ReachMD Healthcare Image
RestartResume

A newly approved treatment option may help patients with metastatic non-small cell lung cancer suffering from MET exon 14 skipping mutations. Find out how.

  • Overview

    Recently approved capmatinib may be a new treatment for patients with metastatic non-small cell lung cancer who have MET exon 14 skipping mutations. To learn more about this emerging treatment option, Dr. Jacob Sands speaks with Dr. Edward Garon from the David Geffen School of Medicine at the University of California in Los Angeles to explore data from the GEOMETRY Mono-1 study.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free